The Technical Analyst
Select Language :
La Jolla Pharmaceutical [LJPC]

Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology

La Jolla Pharmaceutical Price, Forecast, Insider, Ratings, Fundamentals & Signals

La Jolla Pharmaceutical is listed at the NASDAQ Exchange

-0.32% $6.19

/ 15 aug 2022 @ 16:00


La Jolla Pharmaceutical: Main Fundamentals PE comparison

RATING 2022-08-22
B+
Buy
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Neutral
Return On Asset: Neutral
DE: Sell
P/E: Strong Buy
Price To Book: Sell
QUARTER GROWTHS
1/212/213/214/211/222/22
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE 47.62 | sector: PE 0
PE RATIO: COMPANY / INDUSTRY
0x
Company: PE 47.62 | industry: PE 0
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 6.08 - 6.36

( +/- 2.20%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2022-08-22 Rosen Robert Sell 30 000 Stock Option (Right to Buy)
2022-08-22 Rosen Robert Sell 18 000 Stock Option (Right to Buy)
2022-08-22 Rosen Robert Sell 10 000 Stock Option (Right to Buy)
2022-08-22 Rosen Robert Sell 10 000 Stock Option (Right to Buy)
2022-08-22 Rosen Robert Sell 10 000 Stock Option (Right to Buy)
INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 | Sell: 11 680 911

Forecast: 01:40 - $5.73

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $6.19 (-0.32% )
Volume 0.961 mill
Avg. Vol. 0 mill
% of Avg. Vol 0 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for La Jolla Pharmaceutical Company

Last 12 Months

Last 12 months chart data with high, low, open and close for La Jolla Pharmaceutical Company

RSI

Intraday RSI14 chart for La Jolla Pharmaceutical Company

Last 10 Buy & Sell Signals For LJPC

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            La Jolla Pharmaceutical Company

LJPC

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. As of August 22, 2022, La Jolla Pharmaceutical Company operates as a subsidiary of Innoviva, Inc.

Last 10 Buy Signals

Date Signal @
ALPHUSDMar 29 - 06:362.72
LEASHUSDMar 29 - 06:34572.59
FLIPUSDMar 29 - 06:345.05
XMONUSDMar 29 - 06:29911.39
AVTUSDMar 29 - 06:275.77
DIGGUSDMar 29 - 06:24899.52
HTUSDMar 29 - 06:23$0.867
CTXUSDMar 29 - 06:194.96
FUMOUSDMar 29 - 06:149 999
ORCAUSDMar 29 - 06:143.79

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.